Zhi Tong Cai Jing·2026-01-19 07:17Group 1 - The core viewpoint of the article highlights that 康龙化成 (Crown Bioscience) is experiencing a decline in stock price, dropping over 3% to HKD 22.12, with a trading volume of HKD 113 million [2] - On January 15, 康龙化成 announced a plan to place nearly 58.44 million new H-shares at a price of HKD 22.82 per share, representing an approximate 8.5% discount to the closing price on January 14, aiming to raise a net amount of about HKD 1.319 billion [2] - Approximately 70% of the funds raised will be allocated to project construction to enhance laboratory service facilities, drug process development, and production capacity [2] Group 2 - 康龙化成 recently released an earnings forecast, projecting a net profit attributable to shareholders for 2025 to be between HKD 1.614 billion and HKD 1.686 billion, reflecting a decrease of 6% to 10% compared to the previous year [2] - During the reporting period, the company's operating revenue is expected to grow by 13% to 16%, while the net profit after excluding non-recurring gains and losses is anticipated to increase by 36% to 41% year-on-year [2]